Egetis Therapeutics is a startup based in Sweden, most recent round Series-c-plus, 1 tracked investor.
Egetis Therapeutics is a company headquartered in Sweden. Its most recent tracked round is Series-c-plus. Brouky records 1 investor associated with the company.
Egetis Therapeutics is an integrated pharmaceutical company developing late-stage therapies for rare diseases. Its lead product Emcitate (tiratricol) targets MCT8 deficiency (Allan-Herndon-Dudley syndrome) and has received EMA approval, and the company is also developing Aladote (calmangafodipir) for acetaminophen/paracetamol overdose.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.